Clinical Efficacy and Safety of First- or Second-Generation EGFR-TKIs after Osimertinib Resistance for EGFR Mutated Lung Cancer: A Prospective Exploratory Study
K Morimoto, T Yamada, T Takeda, S Shiotsu, K Date… - Targeted Oncology, 2023 - Springer
Background Osimertinib monotherapy is a common treatment for epidermal growth factor
receptor (EGFR)-mutant non-small cell lung cancer (NSCLC); however, standard treatment …
receptor (EGFR)-mutant non-small cell lung cancer (NSCLC); however, standard treatment …
[HTML][HTML] EGFR-Tyrosine Kinase Inhibitor Retreatment in Non-Small-Cell Lung Cancer Patients Previously Exposed to EGFR-TKI: A Systematic Review and Meta …
I Michelon, M Vilbert, CE do Rego Castro… - Journal of Personalized …, 2024 - mdpi.com
We performed a systematic review and meta-analysis to assess the efficacy of EGFR-
tyrosine kinase inhibitors (TKI) retreatment in advanced/metastatic non-small-cell lung …
tyrosine kinase inhibitors (TKI) retreatment in advanced/metastatic non-small-cell lung …
[HTML][HTML] Rechallenge of afatinib for EGFR-mutated non-small cell lung cancer previously treated with osimertinib: a multicenter phase II trial protocol (REAL study)
T Araki, S Kanda, M Komatsu, K Sonehara… - Translational Lung …, 2023 - ncbi.nlm.nih.gov
Background Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have
revolutionized the treatment of advanced non-small cell lung cancer (NSCLC) and …
revolutionized the treatment of advanced non-small cell lung cancer (NSCLC) and …
Clinical efficacy of dacomitinib in rechallenge setting for patients with epidermal growth factor receptor mutant non–small cell lung cancer: A multicenter retrospective …
H Tanaka, H Sakamoto, T Akita, F Ohyanagi… - Thoracic …, 2022 - Wiley Online Library
Background Dacomitinib is the second‐generation epidermal growth factor receptor (EGFR)‐
tyrosine kinase inhibitor (TKI) for mutant non–small cell lung cancer (NSCLC). EGFR‐TKIs …
tyrosine kinase inhibitor (TKI) for mutant non–small cell lung cancer (NSCLC). EGFR‐TKIs …
Effectiveness of EGFR‐TKI rechallenge immediately after PD‐1 blockade failure
K Kaira, K Kobayashi, A Shiono, O Yamaguchi… - Thoracic …, 2021 - Wiley Online Library
Background There is currently insufficient information available on effective therapies that
can be administered to patients with non‐small cell cancer (NSCLC) who develop …
can be administered to patients with non‐small cell cancer (NSCLC) who develop …
[PDF][PDF] Potential of modern circulating cell-free DNA diagnostic tools for detection of specific tumour cells in clinical practice
J Gašperšič, A Videtič Paska - Biochemia Medica, 2020 - hrcak.srce.hr
Review Page 1 Abstract Personalized medicine is a developing field of medicine that has
gained in importance in recent decades. New diagnostic tests based on the analysis of …
gained in importance in recent decades. New diagnostic tests based on the analysis of …
EGFR-TKI rechallenge in patients with EGFR-mutated non-small-cell lung cancer who progressed after first-line osimertinib treatment: A multicenter retrospective …
T Araki, S Kanda, M Obara, T Agatsuma… - Respiratory …, 2024 - Elsevier
Background Rechallenge therapy with epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitor (TKI) is known to confer some clinical benefit for patients with metastatic …
kinase inhibitor (TKI) is known to confer some clinical benefit for patients with metastatic …
Stratification of non-small cell lung adenocarcinoma patients with EGFR actionable mutations based on drug-resistant stem cell genes
X Xie, L Li, L Xie, Z Liu, G Zhang, X Gao, W Peng… - Iscience, 2023 - cell.com
EGFR-TKIs were used in NSCLC patients with actionable EGFR mutations and prolong
prognosis. However, most patients treated with EGFR-TKIs developed resistance within …
prognosis. However, most patients treated with EGFR-TKIs developed resistance within …
Successful afatinib rechallenge in a patient with non‐small cell lung cancer harboring EGFR G719C and S768I mutations
T Masuda, N Sunaga, N Kasahara, K Takehara… - Thoracic …, 2020 - Wiley Online Library
Recent studies have indicated that afatinib is beneficial for patients with non‐small cell lung
cancer (NSCLC) harboring uncommon epidermal growth factor receptor (EGFR) mutations …
cancer (NSCLC) harboring uncommon epidermal growth factor receptor (EGFR) mutations …
Incidence of serious adverse events caused by tyrosine kinase inhibitor treatment following immune checkpoint inhibitor therapy in advanced NSCLC patients with …
Y Shimoda, T Yoshida, J Miyakoshi… - Cancer Immunology …, 2023 - Springer
Background Sequential tyrosine kinase inhibitors (TKIs) following immune checkpoint
inhibitors (ICIs) increases the incidence of serious adverse events (SAEs). However, the …
inhibitors (ICIs) increases the incidence of serious adverse events (SAEs). However, the …